BIX0.F BIOINVENT INTERN. SK 2
- Market cap
- EUR 17.8M
- P/E
- -
- P/B
- 0.94x
- ROE
- -239.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BIX0.F undervalued?
Graham numberThe Graham number of BIOINVENT INTERN. SK 2 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIOINVENT INTERN. SK 2 fundamental analysis
No fundamental analysis for BIOINVENT INTERN. SK 2 yet.
BIOINVENT INTERN. SK 2 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIOINVENT INTERN. SK 2
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tu…
Full company profileBIOINVENT INTERN. SK 2 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BIOINVENT INTERN. SK 2 annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 19.4M | 326M | 71.5M | 44.7M | 226M | 49.3M |
| Operating Income | -278M | -50.5M | -371M | -471M | -351M | -490M |
| EBITDA | - | -27.1M | -320M | -409M | -312M | -472M |
| Net Income | -278M | -42.5M | -330M | -429M | -333M | -481M |
| EPS | -4.76 | -0.65 | -5.02 | -6.53 | -5.06 | -7.32 |
| Balance Sheet | ||||||
| Total Assets | 1.45B | 1.71B | 1.40B | 989M | 671M | 308M |
| Total Liabilities | 80.3M | 106M | 90.5M | 103M | 114M | 107M |
| Shareholders' Equity | 1.37B | 1.61B | 1.31B | 886M | 558M | 201M |
| Cash & Short-term Investments | 911M | 515M | 260M | 435M | 356M | 225M |
| Cash Flow | ||||||
| Operating Cash Flow | -246M | -41.2M | -350M | -380M | -248M | -478M |
| Capital Expenditure | 13.3M | 12.4M | 13.3M | 10.0M | 7.26M | 1.91M |
| Free Cash Flow | -259M | -53.6M | -363M | -391M | -255M | -480M |
| Ratios | ||||||
| ROE | -20.4% | -2.6% | -25.2% | -48.5% | -59.7% | -239.6% |
| ROA | -19.2% | -2.5% | -23.6% | -43.4% | -49.6% | -156.3% |
| Net Profit Margin | -1,436.5% | -13.0% | -462.2% | -960.9% | -147.0% | -976.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIOINVENT INTERN. SK 2 dividends
BIOINVENT INTERN. SK 2 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:25 on Dec 14, 2020.
Who owns BIOINVENT INTERN. SK 2
- Insiders 10.17%
- Institutions 57.68%
- Public & others 32.15%
- Shares outstanding 65.8M
- Free float 31.4M
BIOINVENT INTERN. SK 2 company profile
- Company name
- BIOINVENT INTERN. SK 2
- Ticker
- BIX0.F
- ISIN
- SE0015244520
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 107
- Fiscal year end
- December
- Address
- The Gamma Building, Lund, Sweden, 223 70
- Phone
- 46 4 62 86 85 50
- Website
- bioinvent.com
About BIOINVENT INTERN. SK 2
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
BIOINVENT INTERN. SK 2 management
10- Dr. Martin Welschof Ph.D.President & CEO · born 1961
- Mr. Stefan Ericsson M.B.A.Chief Financial Officer · born 1963
- Mr. Kristoffer Rudenholm HanssonSenior Vice President of Technical Operations · born 1974
- Mr. Björn FrendéusChief Scientific Officer · born 1973
- Ms. Cecilia HofvanderVice President of Investor Relations · born 1967
- Dr. Andres McAllisterChief Medical Officer · born 1956
- Ms. Ingrid TeigeHead of Preclinical Research
- Ms. Sylvie RyckebuschChief Business Officer · born 1965
- Dr. Ingunn Munch LindvigSenior Vice President of Regulatory Affairs · born 1965
- Mr. Ashley R. RobinsonSenior VP of Strategy & Finance · born 1977